an eye drop that is designed to eradicate the Demodex mites, which are too small to see with the naked eye. given as a single drop OU BID for six weeks. and will have a wholesale acquisition cost of $1,850 per prescription… what am I missing?
an eye drop that is designed to eradicate the Demodex mites, which are too small to see with the naked eye. given as a single drop OU BID for six weeks. and will have a wholesale acquisition cost of $1,850 per prescription… what am I missing?
an eye drop that is designed to eradicate the Demodex mites, which are too small to see with the naked eye. given as a single drop OU BID for six weeks. and will have a wholesale acquisition cost of $1,850 per prescription… what am I missing?
an eye drop that is designed to eradicate the Demodex mites, which are too small to see with the naked eye. given as a single drop OU BID for six weeks. and will have a wholesale acquisition cost of $1,850 per prescription… what am I missing?
Apellis is setting the bar a bit high for Tarsus. It’s funny they think they have a billion dollar product on their hands. I’d be shocked if they hit 50 mil at their peak.
Going to be a big hurdle. One and done? What is the relapse rate? Payers wont' pay twice if out of the gate don't see cure going to be hard to recover. How many pts are really in the cue and what is the cadence of a pt. Direct to patient has not proven much success in other areas ROI. This is not Linzess where there was some good return. No take out on this one for 2 years unless they prove quickly that the product works
